• Thiazovivin ROCK Inhibitor for Stem Cell Workflows

  2026-09-02

  Thiazovivin (SKU A5506) is a small-molecule ROCK inhibitor for workflows involving fibroblast reprogramming, induced pluripotent stem cell generation, and post-dissociation human embryonic stem cell survival. It is intended for controlled stem cell research only; product-specific working concentrations are not supplied here, and solutions should not be stored long term.

• Sulfisomidine Workflows for Enzyme and Degradation Studies

  2026-09-01

  Sulfisomidine supports two complementary research workflows: mechanistic inhibition studies centered on hPON1 and PABA-dependent bacterial metabolism, plus transformation and toxicity monitoring in advanced oxidation experiments. This guide connects practical sample preparation, kinetic design, matrix controls, and troubleshooting to help researchers distinguish parent-compound removal from genuine biological risk reduction.

• UK-5099 in Whole-Blood Immunometabolism

  2026-09-01

  UK-5099 (PF-1005023) provides a targeted way to test how mitochondrial pyruvate entry shapes cytokine responses in standardized whole-blood assays. This practical workflow connects mitochondrial metabolism research with glucose-linked functional models while emphasizing dose selection, donor controls, and orthogonal validation.

• Metronidazole: OAT3 and Anaerobe Workflows

  2026-08-31

  Metronidazole supports two complementary research directions: quantitative OAT3 inhibition for transporter and drug-drug interaction studies, and controlled investigations of anaerobic bacteria and protozoa. This practical guide connects assay setup, concentration planning, dual-readout design, and troubleshooting while keeping antimicrobial and transporter effects analytically separate.

• Triiodothyronine (T3) for Cellular Metabolism

  2026-08-30

  Triiodothyronine (T3) provides a controllable perturbation for thyroid hormone receptor activation, transcriptional studies, and cellular metabolism assays. This workflow pairs practical dosing and stability guidance with a careful interpretation of the 2026 cABE study, helping researchers separate validated gene-editing findings from exploratory metabolic applications.

• Polybrene for Mutant p53 Assay Design

  2026-08-29

  Polybrene and Hexadimethrine Bromide can improve viral delivery, but their value in mutant-p53 research depends on separating transduction effects from pharmacological responses. This guide develops an assay-design framework linking delivery control, p53Y220C biology, and reproducible interpretation.

• Recombinant Human FGF-19: Assay Design

  2026-08-29

  Recombinant Human FGF-19 can serve as a defined endocrine-metabolic stimulus in receptor, proliferation, and stress-response experiments. This guide develops an assay framework that connects FGF-19 biology with the WIP1–p38 MAPK–pyroptosis findings in septic kidney injury without overstating the evidence.

• SEMA3E, β-Catenin, and Beige Adipocyte Thermogenesis

  2026-08-28

  The reference study identifies SEMA3E as a previously underdefined regulator of beige adipocyte differentiation and cold-induced thermogenesis in mice. Through genetic manipulation, transplantation, transcriptomics, mitochondrial respiration analysis, and pathway rescue experiments, the authors connect SEMA3E activity to β-catenin signaling and oxidative phosphorylation.

• SAN–Cardiac Plexus Assembloids Model Pacemaker Maturation

  2026-08-28

  This study develops human pluripotent stem cell-derived sinoatrial node–cardiac plexus assembloids that reproduce important structural, molecular, and electrophysiological features of innervation-associated pacemaker maturation. By combining assembloid functional testing with human SAN spatial transcriptomics, the authors identify a CGPO-derived prosaposin–GPR37 signaling program and establish a tractable model for studying neuro-cardiac control of rhythm.

• mRNA-LNP Programming of CAR Macrophages in Cancer

  2026-08-27

  Gu et al. developed a macrophage-targeted mRNA lipid nanoparticle platform for in situ programming of CAR macrophages in peritoneal tumors and used it to compare 36 CAR designs. CAR-Ms incorporating CD3ζ and TLR4 intracellular domains promoted adaptive immune activation, remodeled the tumor microenvironment, and enhanced responses to PD-1/L1 blockade.

• Perphenazine: From D2 Antagonism to Assay Design

  2026-08-27

  Perphenazine is a dopamine D2 receptor antagonist with a broad phenothiazine receptor-binding profile. This article explains how to translate its neuropharmacology, mitochondrial effects, and macrophage host-directed activity into better-designed schizophrenia research and intracellular infection assays.

• BIRB 796 (Doramapimod): p38α MAPK Guide

  2026-08-26

  BIRB 796, also called Doramapimod, is a potent allosteric p38α MAPK inhibitor used in inflammation research, cytokine studies, apoptosis assays, and cancer biology. Its reported biochemical potency and kinase selectivity support precise pathway interrogation, but preclinical activity did not translate into efficacy in Crohn's disease.

• Prednisone Assays: From Mechanism to Matrix Control

  2026-08-26

  Prednisone research benefits from linking immunosuppressive mechanism with rigorous exposure, matrix, and assay controls. This guide applies lessons from advanced botanical LC–MS/MS research to improve lymphocyte apoptosis, cell-cycle, and translational study design.

• SETD7 Depletion Promotes Adipose Browning in Obesity

  2026-08-25

  The reference study identifies SETD7 as a negative regulator of inguinal white adipose tissue thermogenesis. Using genetic depletion, adipocyte culture, metabolic phenotyping, and RNA sequencing, the authors connect SETD7 loss to an Adcy7–Sirt1–Creb1 signaling axis that enhances beige adipocyte activity and protects obese mice from metabolic deterioration.

• Prednisolone for Glucocorticoid Signaling Research

  2026-08-25

  Prednisolone provides a controlled synthetic glucocorticoid input for receptor, inflammation, and immunology assays. This practical guide shows how to formulate, dose, interpret, and troubleshoot the compound while distinguishing validated glucocorticoid workflows from the emerging ERAD-based degradation strategy reported for transmembrane proteins.

452 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page